Where a Woman Lives May Affect Her Breast Cancer Treatment

Publication
Article
OncologyONCOLOGY Vol 22 No 6
Volume 22
Issue 6

Women in the Northeast US are more likely to receive breast-conservation therapy, while those in the South are more often recommended for mastectomies for the treatment of invasive breast cancer, according to a study presented at the 9th Annual Meeting of the American Society of Breast Surgeons (ASBS), held April 30 to May 4 in New York.


Women in the Northeast US are more likely to receive breast-conservation therapy, while those in the South are more often recommended for mastectomies for the treatment of invasive breast cancer, according to a study presented at the 9th Annual Meeting of the American Society of Breast Surgeons (ASBS), held April 30 to May 4 in New York. The study examined data in the massive American College of Surgeons National Cancer Database Benchmark Reports broken down by US census regions. It found that where a woman lives is a significant predictor of her initial invasive breast cancer treatment protocol, independent of such factors as race, age, economic status, and stage at diagnosis.

According to the research, 69.9% of women with breast cancer that has spread beyond the breast ducts or lobules into surrounding breast tissue have only a portion of the breast that contains the tumor removed (lumpectomy), while the remainder are treated with total breast removal (mastectomy). In the Western states, 62.8% receive conservation therapy, whereas conservation rates in the Midwest are 60.7% and in the South are 57.7%.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content